Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) has seen a 2% increase in share price over the past four weeks, closing at $14.52, with a potential upside of 149.7% based on Wall Street analysts' mean price target of $36.25 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $15.00 to a high of $48.00, with a standard deviation of $11.25, indicating variability among analysts [2] - The lowest estimate suggests a 3.3% increase from the current price, while the highest estimate indicates a 230.6% upside [2] Analyst Sentiment - There is strong agreement among analysts regarding MLYS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - Recent trends show that four earnings estimates have been revised higher in the last 30 days, with no negative revisions, leading to a 10.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of MLYS's potential gains, it does provide a useful guide for the direction of price movement [14]